Literature DB >> 8393164

Molecular cloning of murine FLT and FLT4.

H Finnerty1, K Kelleher, G E Morris, K Bean, D M Merberg, R Kriz, J C Morris, H Sookdeo, K J Turner, C R Wood.   

Abstract

A wide range of growth and differentiation processes are regulated by the signalling of receptor tyrosine kinases (RTKs). We have developed a nested polymerase chain reaction (PCR) procedure with degenerate primers, and used it to identify RTKs expressed in murine fetal thymus. A novel RTK, called FLT4, and the murine homologue of FLT were found, and their PCR fragment sequences were used to isolate larger cDNA clones spanning the complete coding regions of these receptors. FLT4 was found to contain an extracellular region similar to the corresponding sequences of FLT and Flk-1, containing seven immunoglobulin domains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393164

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Authors:  Claus Cursiefen; Lu Chen; Magali Saint-Geniez; Pedram Hamrah; Yiping Jin; Saadia Rashid; Bronislaw Pytowski; Kris Persaud; Yan Wu; J Wayne Streilein; Reza Dana
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

Review 2.  Hippocampal plasticity involves extensive gene induction and multiple cellular mechanisms.

Authors:  D Hevroni; A Rattner; M Bundman; D Lederfein; A Gabarah; M Mangelus; M A Silverman; H Kedar; C Naor; M Kornuc; T Hanoch; R Seger; L E Theill; E Nedivi; G Richter-Levin; Y Citri
Journal:  J Mol Neurosci       Date:  1998-04       Impact factor: 3.444

3.  Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas.

Authors:  M Detmar; P Velasco; L Richard; K P Claffey; M Streit; L Riccardi; M Skobe; L F Brown
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.

Authors:  T Davis-Smyth; H Chen; J Park; L G Presta; N Ferrara
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

5.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.

Authors:  J Lee; A Gray; J Yuan; S M Luoh; H Avraham; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

6.  VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.

Authors:  Young-Sup Yoon; Toshinori Murayama; Edwin Gravereaux; Tengiz Tkebuchava; Marcy Silver; Cynthia Curry; Andrea Wecker; Rudolf Kirchmair; Chun Song Hu; Marianne Kearney; Alan Ashare; David G Jackson; Hajime Kubo; Jeffrey M Isner; Douglas W Losordo
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  Pharmacological manipulation of blood and lymphatic vascularization in ex vivo-cultured mouse embryos.

Authors:  Martin Zeeb; Jennifer Axnick; Lara Planas-Paz; Thorsten Hartmann; Boris Strilic; Eckhard Lammert
Journal:  Nat Protoc       Date:  2012-10-11       Impact factor: 13.491

8.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.

Authors:  S Hiratsuka; O Minowa; J Kuno; T Noda; M Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

Authors:  A Kaipainen; J Korhonen; T Mustonen; V W van Hinsbergh; G H Fang; D Dumont; M Breitman; K Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

Authors:  V Joukov; K Pajusola; A Kaipainen; D Chilov; I Lahtinen; E Kukk; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.